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Prior to this study, very few studies in Cameroon have ddressed co-infection of HIV and hepatitis in 
pregnancy. The aim of this study was to screen pregnant women living in the Buea Health District for Human 
Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C virus (HCV) and determine how the 
prevalence of mono and co-infections relates to immunity. Eligible and consenting women were interviewed 
using a standardized questionnaire. After which 10 ml of whole blood was collected from 406 pregnant 
women. All specimens were tested for HIV, HBV and HCV using Determine HIV1/2 (Abbott Co. Ltd., Japan), 
SD Bioline (Standard Diagnostics, INC., USA) and ELISA (Murex Biotech Limited, Temple Hill, UK; 
ABBOTT Laboratories, Wiesbaden, Germany). The prevalence of HIV, HBV and HCV mono-infection in this 
study was 34(8.37%), 40(12.1%) and 28(6.89%) respectively. HIV/HBV, HIV/HCV, HBV/HCV and 
HIV/HBV/HCV multiple infection rates were 6(1.48%), 7(1.72%), 5(1.23%) and 2(0.49%) respectively and 
there was no statistical association between accessed ri k factors and multiple viral infections in Pregnancy. 
Amongst women with a positive HIV result, those co-infected with HBV and HCV had the least mean CD4+ T-
cell lymphocyte counts (531.50 ± 6.18) while those inf cted only with HIV had the highest mean CD4+ T-cell 
lymphocyte counts (620.22 ± 165.27). Co-infection of HIV, HBV and HCV reduced the immune competence-
CD4+ T cell counts, in pregnant women more than those who ere HIV mono-infected.  
© 2016 International Formulae Group. All rights reserved 
 





People living with HIV/AIDS (PLWH) 
were 34 million (Range 31.4-39.5 million) 
and AIDS deaths were 1.7million (Range 1.5-
1.9 million) (Schwartlander et al., 2011). In 
2013, WHO reported an increase in these 
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figures stating that by the end of 2012, PLWH 
had increased to 35.3 million and 1.6 AIDS 
death occurred (WHO-HIV/AIDS Report, 
2013). Due to the high estimated numbers of 
pregnant women living with HIV, Cameroon 
is one of 22 priority countries identified in the 
World Health Organization’s “Global Plan” as 
a key target for HIV control and interventions 
(Gaynes et al., 2012). 
Pregnancy is considered high risk when 
a woman is hepatitis B virus (HBV) infected 
and there is a 20% chance of transmission to 
the unborn infant. HBV is the most common 
form of Hepatitis worldwide and chronic 
carriers continue to transmit the virus years 
before symptoms appear. The mode of 
transmission in areas of high endemicity is 
mostly vertical (Tran, 2010; Hwang and 
Cheung, 2011; Komatsu et al., 2012). Of the 
hepatotrophic viruses (hepatitis A, B, C, D 
and E), hepatitis B virus is most virulent and 
most versatile and is probably also the most 
prevalent of all viruses that affect humans 
(Park, 2011). In a study carried out in 
Ethiopia, it was found that the sero-prevalence 
of HBsAg in pregnant women was 3.7% 
(Awole and Gebre-Selassie, 2005; Esan et al., 
2014; Molla et al., 2015). 
In Cameroon, studies carried out 
revealed that the prevalence of hepatitis B 
surface antigen in rural general populations 
was greater than 8% (Kfutwah et al, 2012). 
Presently, much of the work being done in 
Cameroon on HBV is focused on hepatitis 
among HIV patients and in one of such 
studies, the prevalence of HBV among adults 
starting ARV therapy was found to be 8.3% 
(Laurent et al., 2010).In the North West 
Region of Cameroon, it was determined that 
the prevalence of hepatitis B surface antigen 
in the general population was at 12.6% and 
male patients were more likely to have 
positive results than female patients (Zoufaly 
et al., 2011). More still has to be done in the 
South West Region of Cameroon as little data 
is available concerning the prevalence of 
HBsAg and hepatitis B virus (HBV) infection 
may go undetected. Unawareness of an 
ongoing infection delays the diagnosis of 
HBV-related liver disease and favors the 
spread of the virus (Chan et al., 2012; Brouard 
et al., 2013; Molla et al., 2015). 
 In a study to demonstrate unawareness 
of HBV infection among patients in a clinic in 
Italy by Ippolito et al. (2011), it was noticed 
that up to 40.3% of the participants were not 
aware of their infection. The age group most 
likely to be affected around the world is the 
newborn population, particularly in areas with 
a high prevalence of disease and lack of 
identification of infected women whose 
infants are at risk for becoming chronic 
carriers and in regions with low spread 
perinatal screening and in- adequate use of 
newborn prophylaxis, horizontal transmission 
secondary to exposure to contaminated blood 
products, body fluids, or sexual contact 
become the primary modes of transmission of 
HBV in the young adult population (Komatsu 
et al., 2012). 
Hepatitis C virus (HCV) which is also 
being reported is an RNA virus known to 
infect humans and chimpanzees, causing 
similar disease in these 2 species. HCV is 
most often transmitted parenterally but is also 
transmitted vertically and sexually (Karoney 
and Silika, 2013). Hepatitis C virus (HCV) is 
up to 4 times more infectious than HIV and it 
is the leading cause of chronic liver cancer 
(Karoney and Silika, 2013). Drops of the virus 
can get dry and remain infectious for 6 weeks 
at room temperature. It also requires less 
exposure than HIV to cause infection (Te and 
Jensen, 2010). The prevalence of HCV in the 
general population in Africa ranges between 
0.1% and 17.5%, depending on the country 
(Karoney and Silika, 2013). Little data is 
available on HCV morbidity and mortality in 
Africa. Of those HCV-infected patients who 
develop chronic liver disease 1.6% progress to 
Hepatocellular carcinoma (HCC), a condition 
R. E.TANJONG et al. / Int. J. Biol. Chem. Sci. 10(1): 2 9-231, 2016 
 
 221
with a mortality rate >80% (Maheshwari and 
Thuluvath, 2010). 
The prevalence of HCV infection in 
Cameroon is among the highest in the world, 
7.9% as reported by Njouom et al. (2005) and 
comparable to that documented in the 
schistosomiasis-endemic areas of Egypt 
(Frank et al., 2000). Just like in Egypt, the 
high prevalence of HCV has been 
incriminated to interventions for tropical 
disease control during the colonial era 
(Jacques et al., 2010) and the use of 
unsterilized pricking equipment used for mass 
treatment on the general population with 
parenteral anti-schistosomal therapy from the 
1920s to the 1980s or traditional practices 
(Mohamoud et al., 2013). Despite its high 
prevalence and highly infectious nature, HCV 
remains under-diagnosed and under reported 
in Africa (with the exception of Egypt). Low 
risk of transmission of HCV from mother to 
child has been reported in Cameroon (Pépin et 
al., 2010; Njouom et al., 2011). 
All the three viruses have some 
common areas of interactions such as; shared 
routes of transmission- in blood either 
sexually or by injection drug use and mother-
to-child-transmission (M-T-C). HBV like HIV 
possess reverse transcriptase (Mims et al., 
2006) and 5-25% of the 35.3 million people 
living with HIV worldwide are co-infected 
with either HBV or HCV or both (Okeke et 
al., 2012). The highest numbers of those co-
infected are in low income countries (Okeke 
et al., 2012). 
This study was carried out because 
previous studies on HIV and hepatitis co-
infection in Cameroon have been on the 
general population and 90% of HBV 
transmissions are vertical with more women 
transmitting the Hepatitis B surface antigen 
(HBsAg). Also, it was to provide relevant data 
on current prevalence of HIV and hepatitis co-
infection and their correlation to immunity 
(CD4+ T-cell counts) in pregnant women in 
the Buea Health District, South West Region 
of Cameroon. 
 
MATERIALS AND METHODS 
Ethical considerations 
Ethical approval for this work was 
obtained from the Regional Delegation of 
Public Health, Buea, South-West Region and 
from the Ministry of Public Health, Yaounde, 
Cameroon. Participation was voluntary. A 
written consent was sought from all 
participants. All procedures were standard and 
only involved minimal risk to the participants.  
 
 Study setting/Study population/ Eligibility 
criteria  
Study participants were recruited from 
Antenatal Clinics (ANCs) in the Buea Health 
District of Cameroon. A total of 407 
participants were interviewed and criteria for 
recruitment were being pregnant and willing 
to participate in the study. 
 
Sample collection 
This was a demographic cohort study 
carried out in 2010. All eligible and 
consenting women were interviewed using a 
standardized questionnaire. After interview, 
the following samples were collected from 
each participant: 10 ml of whole blood (5 ml 
was put in dry tubes to obtain serum while the 
remaining 5 ml was put in EDTA tubes to 
obtain plasma). The blood samples collected 
were put in tube racks and transported in an 
ice-box containing ice to the Faculty of Health 
Science Laboratory, where all laboratory 
assays were done. Participants’ results were 
returned and those of HIV-positive women 
after post-test counselling were directed into 
regular care by the nurses in the antenatal 
clinics. Two and a half milliliter (2.5 ml) of 
whole blood was equally collected from 
children born of HIV positive mothers 18 
months after delivery to test for HIV. 
 




All specimens were tested for HIV, 
HBV and HCV using Determine HIV1/2 
(Abbott Co. Ltd., Japan), SD Bioline 
(Standard Diagnostics, INC., USA) and 
ELISA (Murex Biotech Limited, Temple Hill, 
UK; ABBOTT Laboratories, Wiesbaden, 
Germany).The CD4+T-cell absolute count was 
determined using the Partec Cyflow Counter 




Data was entered and checked for 
completeness using excel and analyzed using 
SPSS. Differences between groups were 
established for continuous data using the 
student t-test and the analysis of variance 
(ANOVA) while the Chi-square (X2) analysis 
was used to establish difference between 
groups for categorical data. The correlation 
coefficient was calculated to establish a 
correlation between two variables. A P- value 
< 0.05 was considered statistically significant. 
 
RESULTS  
Description of participants’ characteristics 
A total of 407 pregnant women were 
approached in the study but 406 consented 
and this gave a response rate of 95.54%. 
Slightly less than one third (30.5%) of the 
participants were primiparous. The age of 
participants ranged from 15 to 47 years with a 
mean of 26 ± 5.56 (Table 1). 
 
Prevalence of HIV, HBV and HCV mono 
and multiple infections 
Twenty (4.93%) of the 406 pregnant 
women tested positive for two or all three 
infections (HIV, HBV and HCV) screened in 
this study. Six [1.48% (P=0.297)] were found 
to be co-infected with HIV and HBV, 07 
[1.72% (P=0.135)] with HIV and HCV, 05 
[1.23% (P=0.30)] with HCV and HBV, and 2 
[0.49% (P=0.293)] were infected with all 
three infections as illustrated in Figure 1. 
These results were not statistically significant 
and none of the risk factors were associated 
with multiple infections as illustrated on Table 
2. 
 
Mother–to-Child HIV transmission 
amongst HIV positive pregnant women 
Of the 34 HIV infected pregnant 
women followed up in this study, 32 (94.12%) 
gave birth to life children, and 3 (8.82%) were 
lost to follow up, giving a successful follow 
up rate of 29 (85.29%). Amongst the 29 
children born of HIV positive mothers, 8 
(27.59%) were diagnosed to be HIV positive.  
The mean CD4+T-cell count of the 29 
mothers who gave birth to life children was 
251.57 ± 80.33 (95% CI: 221.01-282.13) 
while that of mothers who transmitted the 
virus to their children was 202.1± 46.01 (95% 
CI: 163.66-240.59).  
 
The impact of HBV and HCV co-infection 
on the immune competence of HIV positive 
pregnant women                            
Amongst women with a positive HIV 
result, those co-infected with HBV and HCV 
had the least mean CD4+ T-cell lymphocyte 
counts (531.50 ± 6.18) while those infected 
only with HIV had the highest mean CD4+ T-
cell lymphocyte counts (620.22 ± 165.27) and 
there was a significant difference between the 
CD4+ T-cell lymphocyte counts of HIV 
positive only and HIV negative pregnant 
women (P= 0.002).  Amongst those who had a 
positive test result for at least one viral 
infection, those with a positive test result for 
both HBV and HCV had the highest mean 
CD4+ T-cell lymphocyte counts (843.00 ± 
223.54) and there was no significant 
difference between the CD4+ T-cell 
lymphocyte counts of HCV positive and 
negative pregnant women (P= 0.602) as 
illustrated in Figure 2. 
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Table 1: Distribution of Participants’ Characteristics. 
 
Age group  Frequency Percentages Cumulative Percentages 
≤25 years 187 46.1 46.1 
≥ 26 years 219 53.9 100.0 
Marital status    
Unmarried 144 35.5 35.5 
Married 256 63.1 98.5 
Widow/divorced 6 1.5 100.0 
Period of gestation    
1st trimester  30 7.4 7.4 
2nd trimester 160 39.4 46.8 
3rd trimester 216 53.2 100.0 
Number of gravidity     
1 141 34.7 34.9 
2 102 25.1 60.1 
3 79 19.5 79.7 
4 49 12.1 91.8 
5 22 5.4 97.3 
6 7 1.7 99.0 
7 2 0.5 99.5 
8 2 0.5 100.0 
Education    
No formal education 3 0.7 0.7 
Primary 119 29.3 30.0 
Secondary 178 43.8 73.9 
Tertiary 106 26.1 100.0 
Occupation    
Semi-skilled 176 43.3 43.3 
Skilled 86 21.2 64.5 
Student/apprentice 80 19.7 84.2 
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Table 2:  Risk factors to multiple viral infections in pregnancy. 
 
Risk factors HIV/HBV  p-Valve HIV/HCV  p-Valve HBV/HCV  p-Valve HIV/HBV/HCV  p-Valve 
Age Group Neg Pos  
0.529 
Neg Pos  
0.349 
Neg Pos  
0.784 
Neg Pos  
0.911 ≤ 25 185 2 185 2 185 2 186 1 
≥26 215 4 214 5 216 3 218 1 
Marital status      
Unmarried 140 4  
0.271 
141 3  
0.254 
142 2  
0.946 
142 2  
0.161 Married 254 2 252 4 253 3 256 0 
Widow/Divorce 6 0 6 0 6 0 6 0 
Educational level     
No formal education 3 0  
 
0.727 
3 0  
 
0.369 
3 0  
0.533 
3 0  
 
0.462 
Primary 118 1 117 2 119 0 119 0 
Secondary 174 4 173 5 175 3 176 2 
Tertiary 105 1 106 0 104 2 106 0 
Occupation     
Unskilled 173 3  
 
0.473 
172 4  
 
0.454 
175 1  
 
0.673 
175 1  
 
0.506 
Skilled 85 1 85 1 84 2 86 0 
Student/apprentice 80 0 80 0 79 1 80 0 
House wife/Unemployed 62 2 62 2 63 1 63 1 
 




Cameroon is part of Sub-Saharan 
Africa, a region where 68% of all people 
living with HIV reside (UNAIDS, 2013). It is 
estimated that 550,000 of the world’s 35.3 
million people are currently living with HIV 
in Cameroon (WHO-HIV/AIDS, 2013) with 
an HIV prevalence of 5.5% (Gaynes et al., 
2012). The South West Region of Cameroon 
represents one of the high HIV burden regions 
with an estimated 8% prevalence (Ndjeng, 
2013). This study reveals an HIV prevalence 
of 8.4% in pregnant women attending 
antenatal clinics the Buea.  
The prevalence of HBsAg among 
pregnant women was found to be 12.1%. This 
is relatively high in view of the fact that a vast 
majority of participants were asymptomatic. 
In comparison with studies from other parts of 
the same country, the prevalence reported in 
this study was higher than the 1.2%, 7.85%, 
7.7% and 9.7% reported by Thumamo and 
Asoquo (2004), Kfutwah et al. (2012), 
Fomulu et al. (2013) and Frambo et al. (2014) 
respectively. This difference may be because 
of different socioeconomic status and the 
natural difference attached to different 
geographic zones. Our prevalence was also 
higher than the 5.4% reported in the early 
nineties by Ndumbe et al. (1994) in rural 
pregnant women in Cameroon. We however 
had similar results with Florent et al. (2012), 
who found a prevalence of 12.14% amongst 
blood donors at the Blood Bank of the Central 
Hospital, Yaoundé (Cameroon). Similar 
results were also recorded by Zoufaly et al. 
(2012) who found a prevalence of 12.6% 
among HIV patients initiating antiretroviral 
therapy in the North-West Region of 
Cameroon. We however expected this high 
prevalence and this is in conformity with the 
established fact that HBsAg is endemic in 
African countries south of the Sahara desert of 
which Cameroon is among (Ndumbe et al., 
1994). This level of carrier state in women of 
reproductive age will suggest that there is a 
high risk of mother-to-infant transmission in 
the Buea Health District. However, HBsAg 
carrier state alone in a pregnant woman does 
not put the fetus at a huge risk of being 
infected, instead, pregnant women who are 
positive both for HBsAg and HBeAg are more 
likely to infect their babies. Transmission does 
not only depend on HBsAg and HBeAg status 
but also on anti-HBeAg status. Anti-HBeAg 
positivity tends to prevent transmission 
(Okada et al., 1976;  Umar et al., 2013). 
Africa has the highest WHO estimated 
regional HCV prevalence (5.3%). The 
prevalence of HCV in the general population 
in Africa ranges between 0.1% and 17.5%, 
depending on the country (Karoney and 
Silika, 2013). The prevalence of HCV in this 
study is 6.9%. Many studies have shown that 
the prevalence of HCV increase with Age. 
Participants in our study had ages that ranged 
from 15 to 47 years with a mean age of 26 ± 
5.56. Though there was no statistically 
significant difference between those aged less 
than or equal to 25 years and those greater 
than 25 years in this study, we however 
noticed that those with ages greater than 25 
years were more infected than those less than 
25 years.  
The overall hepatitis (B and C) and 
HIV co-infection rate in this study was 4.9%. 
This implies that one in every twenty pregnant 
women is at risk of transmitting both HIV and 
HBV or HCV, a deadly combination for 
which a real cure does not yet exist, not only 
to their spouse but to their future offspring. 
Appropriate measures need to be taken to 
reduce the spread of these infections. 
Although it is postulated that trans-placenta 
HCV transmission is very rare, the risk of 
mother to child HCV transmission remains 
very high as the child may become infected 
either at delivery or by the intimate contact 
between mother and child (Murad et al., 
2013).  
Lower prevalence rates for the co-
infection of HIV-HBV and HIV-HCV were 
recorded by Florent et al. (2012) amongst 
blood donors in the Yaoundé Central Hospital 
blood bank. Higher prevalence of HIV-HBV 
and HIV-HCV were however obtained by 
Laurent et al. (2010) and Florent et al. (2012) 
in Yaounde. Indeed, Laurent et al. (2010) 
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found among HIV-positive patients, 8.3% and 
12.4% co-infections with HBV and HCV, 
respectively. But these results were obtained 
from 169 HIV-positive people eligible for 
antiretroviral therapy, thus at a more advanced 
stage of the HIV infection. 
In this study, the prevalence of Mother 
to child transmission of HIV is 27.6%. In 
well-resourced health care systems, such as 
those in the United States, there has been 
dramatic progress in reducing mother to child 
transmission of HIV infection. Early 
identification of HIV infection in pregnant 
women through routine antenatal HIV testing; 
immediate assessment of HIV-infected 
pregnant women for their need for treatment 
for their own health; and provision of 
antiretroviral treatment when needed or 
antiretroviral prophylaxis if therapy is not yet 
required has substantially reduced the risk of 
infection among infants during pregnancy and 
delivery. When combined with elective 
caesarean delivery and complete avoidance of 
breastfeeding, these interventions have 
reduced the risk of HIV transmission to 1%–
2% (Townsend et al., 2008). 
Our study shows that all eight (100%) 
HIV infected children born of HIV infected 
mothers where born through the vaginal route. 
87.5% of these pregnancies where not planned 
and their mothers were not on any ART. This 
proves the non-application of WHO 
recommendations on measures to prevent 
mother to child HIV transmission in most 
resource limited countries. Since 2004, WHO 
guidelines recommended the use of more 
efficacious multidrug antiretroviral regimens 
for the treatment and prevention of mother to 
child HIV transmission. These measures also 
included the use of highly active antiretroviral 
therapy for women with advanced disease and 
short course dual prophylaxis for healthier 
women not yet eligible for treatment (WHO, 
2009).  
The application of WHO 
recommendations remains a major challenged 
in resource limited countries such as 
Cameroon for many reasons such as 
maintaining adequate supplies of HIV tests 
kits and medications, a shortage of maternal 
and child health staff, the reliance on medical 
doctors for antiretroviral treatment initiation 
and the weak linkages between HIV diagnosis 
in pregnancy and antiretroviral therapy 
services, which often preclude women from 
being fast-tracked into HIV care and treatment 
programs. As a result of this limited capacity, 
many countries are unable to adapt their 
existing health systems according to World 
Health Organization preventing mother to 
child HIV transmission guidelines, which are 
amended as new evidence becomes available 
and more cost-effective in the long-term. 
Therefore, many health services are not 
providing HIV-infected women with the most 
effective drugs. One example of this is the use 
of single-dose nevirapine, an antiretroviral 
drug which, despite no longer being 
recommended by the WHO, in 2011 is still 
being used in many countries for preventing 
mother to child HIV transmission including 
Cameroon. 
Findings from our study also revealed 
that the mean CD4+T cell count of the  mother 
who failed to transmit HIV to their children 
was 503.14 ± 160.665 (95% CI: 
442.02,564.25) while that of mothers who 
transmitted the virus to their children was 
392.38 ± 186.61 (95% CI: 236.36, 548.39). 
Our study revealed that women who were 
tested positive for HIV, HBV and HCV triple 
infection had lower CD4+ cell counts than 
those who were either co-infected with 
HIV/HCV or HIV/HBV and even those who 
tested positive for only HIV infection. These 
findings were similar to those of Olufemi et
al. (2009) in Nigeria who demonstrated that 
the mean CD4+ T cell counts of those who 
test positive HIV/HCV and HIV/HBV co-
infections were lower than those who tested 
positive for HIV mono infection. However, 
studies carried out by Yitayih et al. (2013) 
showed that there was no statistically 
significant CD4 count mean difference 
between HIV mono-infected, HIV/HBV and 
HIV/HCV co-infected study participants. 
These controversial results may be partly due 
to the differences in the immune status of the 
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study participants or it may be due to the viral 
hepatitis. A study by Hooja et al. (2015) also 
proved that HIV infection may accelerate the 
progression of hepatic complications.  
We also wish to acknowledge that our 
study failed to consider some factors such as 
duration of antiretroviral therapy for those 
already on antiretroviral therapy, assess if the 
participants who were infected with HCV and 
HBV were acute or chronic carriers. All of 
these factors may have an indirect effect on 




The prevalence of HIV, HBV and HCV 
mono infections in pregnant women living in 
the Buea, South West Region of Cameroon 
remains relatively higher than most other 
areas in which similar studies were carried out 
in Cameroon. The co-infection of HIV, HBV 
and HCV in pregnant women in this study 
was however lower than in the general 
population and multiple infection of HIV, 
HBV and HCV reduced the immune 
competence (CD4+ T-cell counts) in pregnant 
women more than those who were HIV mono-
infected.  
Over a quarter of Children born of HIV 
positive pregnant women were tested positive 
for HIV. The non-application of WHO (2009) 
measures to prevent mother to child HIV 
transmission such as the use of antiretroviral 
treatment when needed or antiretroviral 
prophylaxis if therapy is not yet required, 
programmed pregnancies, elective caesarean 
delivery and complete avoidance of 
breastfeeding have been incriminated as main 
factors associated with mother to child HIV 
transmission in this study.  
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